A Single-Arm Study to Provide Boceprevir Treatment in Subjects With Chronic Hepatitis C Genotype 1 Deemed Nonresponders to Peginterferon/Ribavirin in Previous Schering-Plough Boceprevir Studies.

Trial Profile

A Single-Arm Study to Provide Boceprevir Treatment in Subjects With Chronic Hepatitis C Genotype 1 Deemed Nonresponders to Peginterferon/Ribavirin in Previous Schering-Plough Boceprevir Studies.

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Apr 2017

At a glance

  • Drugs Boceprevir (Primary) ; Peginterferon alfa-2b; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PROVIDE
  • Sponsors Merck & Co
  • Most Recent Events

    • 01 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Oct 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2008-004556-71).
    • 19 Sep 2012 Planned end date changed from 1 Jan 2013 to 1 Dec 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top